SFA-002, an oral small-molecule treatment for mild-to-moderate psoriasis, met its primary safety endpoint with no treatment-related adverse events or toxicities observed in Phase 1b trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.